Skip to main content
OpenTrials
Completed

NCT Number: NCT01402804

NSAIDs in Coronary Artery Disease Patients

Introduction:

Different groups already showed in retrospective subgroup analyses, that there is an increased risk for cardiovascular events in patients on a simultaneous ASA/NSAID treatment.

Methods:

Light-Transmission aggregometry

Hypothesis:

Simultaneous administration of different NSAIDs and ASA impair the platelet inhibiting effect of ASA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

CAD

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Heinrich-Heine-University

Düsseldorf, North Rhine-Westphalia, 40225, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients on a simultaneous ASA, NSAID treatment
  • > 18 years

Exclusion criteria

  • unconsciousness, not able to consent
  • reanimation, cardiac shock

Treatment and study plan

Primary outcomes

  1. Thromboxane-levels and light-transmission aggregometry in response to arachidonic acid

    Time frame: During hospital stay

Sponsors and collaborators

Lead sponsor

Heinrich-Heine University, Duesseldorf

Other

Registry information

Official study title

Non-steroidal Anti-inflammatory Drugs Impair the Platelet Inhibiting Effect of Acetylsalicylic Acid in Coronary Artery Disease Patients

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Jul 26, 2011
Registry last updated
Nov 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.